Pharvaris N.V. - Ordinary shares, par value Euro 0.12 per share (PHVS)

CUSIP: N69605108

Q2 2022 13F Holders as of 30 Jun 2022

Holder snapshot 6 signals
Share change
+667,950
SEC-reported price per share
$22.10
Number of holders
20
Value change
+$14,911,660
Number of buys
8
Number of sells
9
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
72,909,667

Security key

N69605108

Report period

Q2 2022

Institutions

20

Top holders

10

Ownership snapshot

Top reported holders of PHVS - Pharvaris N.V. - Ordinary shares, par value Euro 0.12 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Foresite Capital Manageme...
Disclosed value leader
Foresite Capital Manageme...
Comparable rows
0/15
Latest evidence
31 Mar 2022
13F Highest disclosed value: $59,155,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Foresite Capital Management IV, LLC has the largest disclosed position value at $59.16M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Foresite Capital Management IV, LLC's linked filing trail.
Disclosed position value Top 5
Foresite Capital Management IV, LLC $59.16M
Bain Capital Life Sciences Invest... $57.68M
VIKING GLOBAL INVESTORS LP $46.38M
GENERAL ATLANTIC, L.P. $43.89M
venBio Partners LLC $41.77M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Foresite Capital Management IV, LLC
13F
Company
13F
—
denominator unverified
$59,155,000
3,261,926 shares
— 31 Mar 2022
Bain Capital Life Sciences Investors, LLC
13F
Company
13F
—
denominator unverified
$57,680,000
3,180,601 shares
— 31 Mar 2022
VIKING GLOBAL INVESTORS LP
13F
Company
13F
—
denominator unverified
$46,382,000
2,480,319 shares
— 31 Mar 2022
GENERAL ATLANTIC, L.P.
13F
Company
13F
—
denominator unverified
$43,890,000
2,420,155 shares
— 31 Mar 2022
venBio Partners LLC
13F
Company
13F
—
denominator unverified
$41,771,000
2,303,310 shares
— 31 Mar 2022
DEERFIELD MANAGEMENT COMPANY, L.P.
13F
Company
13F
—
denominator unverified
$28,600,000
1,577,078 shares
— 31 Mar 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
20
Shares
22,353,338
Rows available
20
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2022 vs Q3 2025 Across Filers

Q3 2025 holders
83
Q2 2022 holders
20
Holder diff
-63
Investor Q3 2025 Shares Q2 2022 Shares Share Diff Share Chg % Q3 2025 value Q2 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .